3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Wide surgical resection; radiotherapy for limb and trunk tumours; no morcellation of uterine masses that could be sarcoma; adjuvant chemotherapy not standard.
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Doxorubicin plus trabectedin (LMS-04) or doxorubicin alone; gemcitabine-docetaxel as an alternative, especially in uterine disease.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.
A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.
The first chemotherapy to extend life in prostate cancer (2004), now part of triplet therapy at first metastatic diagnosis.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · Doxorubicin 75 mg/m2 with placebo, ANNOUNCE control arm (49.0%) | - | 49% |
| Alopecia · Doxorubicin with cyclophosphamide (AC), adjuvant breast cancer, N=1492; the label gives no sarcoma figure | 92% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · ET743-SAR-3007, trabectedin alone in liposarcoma or leiomyosarcoma, laboratory values, US label; the OVA-301 combination abstract gives no rate | 66% | 43% |
| ALT increase · ET743-SAR-3007, trabectedin alone, laboratory values, US label; OVA-301 reported grade 3-4 transaminase rises as more common with the combination but transient | 90% | 31% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.
Trabectedin, pazopanib, dacarbazine-based regimens, aromatase inhibitors in hormone receptor-positive low-grade uterine disease; metastasectomy for limited lung spread.
A chemotherapy derived from a sea squirt, used with liposomal doxorubicin in relapsed ovarian cancer in Europe and for sarcomas.
Pazopanib is the only multi-kinase inhibitor approved for soft-tissue sarcoma (excluding fat-derived tumours), used after chemotherapy fails.
Daily pills that stop the body making oestrogen after menopause, the backbone of hormone therapy for most breast cancers.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · ET743-SAR-3007, trabectedin alone in liposarcoma or leiomyosarcoma, laboratory values, US label; the OVA-301 combination abstract gives no rate | 66% | 43% |
| ALT increase · ET743-SAR-3007, trabectedin alone, laboratory values, US label; OVA-301 reported grade 3-4 transaminase rises as more common with the combination but transient | 90% | 31% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Fatigue · PALETTE (VEG110727) pazopanib arm, N=240 | 65% | 14% |
| ALT elevation · PALETTE (VEG110727) pazopanib arm, laboratory data | 46% | 10% |
| Hypertension · PALETTE (VEG110727) pazopanib arm, N=240 | 42% | 7% |
| Pneumothorax · PALETTE (VEG110727), 8 of 240 patients | 3.3% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Arthralgia/arthritis · BIG 1-98, letrozole monotherapy arm (n=2448), US label; myalgia 9.0% | 25.4% | 3.4% |
| Fatigue · BIG 1-98, letrozole monotherapy arm (lethargy, malaise, asthenia), US label | 9.6% | 0.2% |
| Hot flushes · BIG 1-98, letrozole monotherapy arm, US label | 33.5% | - |
| Bone fracture (during 5 years of treatment) · BIG 1-98, letrozole arm at median treatment duration of 60 months (7.2% with tamoxifen), US label | 10.2% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.